Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

As Drug Development Costs Skyrocket, AI Offers Some Hope

Posted on November 20th, 2017 by in Pharma R&D

Last year, researchers from the Tufts Center for the Study of Drug Development published a paper in the Journal of Health Economics that provided an assessment of the current cost for pharmaceutical companies to discover and develop new drugs and biologics. Continue reading “As Drug Development Costs Skyrocket, AI Offers Some Hope” »

Myelo Therapeutics Takes on Unmet Needs in Cancer

Posted on November 17th, 2017 by in Pharma R&D

Many pharmaceutical and biotechnology start-ups have been founded for the purpose of taking on unmet needs. It has often been difficult for the larger, more established pharma companies to focus on these narrower problems, so the leaner, scrappier start-ups are putting their passion and brainpower to the challenges that have yet to be tackled. Continue reading “Myelo Therapeutics Takes on Unmet Needs in Cancer” »

Compliant Monitoring of Adverse Events

Posted on May 24th, 2017 by in Pharmacovigilance

Developing and maintaining a solid strategy for screening for adverse events is critical for every pharmaceutical company. Without one, an adverse event could be reported in scientific literature without the company knowing — and failure to report it to the regulatory authorities could result in a serious warning. Continue reading “Compliant Monitoring of Adverse Events” »

How Are You Handling Big Data & Innovation?

Posted on April 28th, 2017 by in Pharma R&D

Although every pharmaceutical company still hopes to find the next blockbuster drug, today’s R&D departments are becoming increasingly focused on developing more targeted therapies. It is the advent of Big Data that has made it possible for researchers to advance precision medicine and targeted drugs Continue reading “How Are You Handling Big Data & Innovation?” »

  1. 1
  2. 2
  3. 3